Search research articles
Contact Us
Filters
Showing results (431-440 of 441) with videos related to
Page
of 45
Sort By:
Nature
|
November 7, 2006
Global trends of whole-genome duplications revealed by the ciliate Paramecium tetraurelia
Jean-Marc Aury, Olivier Jaillon, Laurent Duret, et al.
Lancet (London, England)
|
August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
C Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
The Lancet. Oncology
|
May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Martin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology
|
December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology
|
April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma
C Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
The Journal of Experimental Medicine
|
November 11, 2024
Human ITGAV variants are associated with immune dysregulation, brain abnormalities, and colitis
Sina Ghasempour, Neil Warner, Rei Guan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 30, 2018
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
Anne S Tsao, O Wolf Lindwasser, Alex A Adjei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 24, 2019
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach
Andrew G Nicholson, Jennifer L Sauter, Anna K Nowak, et al.
Acta Neuropathologica
|
March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
C Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.
Page
of 45
Search research articles
Search
Showing results (431-440 of 441) with videos related to
Sort By:
Page
of 45
Nature
|
November 7, 2006
Global trends of whole-genome duplications revealed by the ciliate Paramecium tetraurelia
Jean-Marc Aury, Olivier Jaillon, Laurent Duret, et al.
Lancet (London, England)
|
August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
C Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
The Lancet. Oncology
|
May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Martin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology
|
December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology
|
April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma
C Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
The Journal of Experimental Medicine
|
November 11, 2024
Human ITGAV variants are associated with immune dysregulation, brain abnormalities, and colitis
Sina Ghasempour, Neil Warner, Rei Guan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 30, 2018
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
Anne S Tsao, O Wolf Lindwasser, Alex A Adjei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 24, 2019
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach
Andrew G Nicholson, Jennifer L Sauter, Anna K Nowak, et al.
Acta Neuropathologica
|
March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
C Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.
Page
of 45